140 related articles for article (PubMed ID: 9858943)
1. Valproic acid inhibits proliferation and changes expression of CD44 and CD56 of malignant glioma cells in vitro.
Knüpfer MM; Hernáiz-Driever P; Poppenborg H; Wolff JE; Cinatl J
Anticancer Res; 1998; 18(5A):3585-9. PubMed ID: 9858943
[TBL] [Abstract][Full Text] [Related]
2. Different effects of valproic acid on proliferation and migration of malignant glioma cells in vitro.
Knüpfer MM; Pulzer F; Schindler I; Hernaíz Driever P; Knüpfer H; Keller E
Anticancer Res; 2001; 21(1A):347-51. PubMed ID: 11299760
[TBL] [Abstract][Full Text] [Related]
3. Interferon gamma inhibits proliferation and hyaluronic acid adhesion of human malignant glioma cells in vitro.
Knüpfer MM; Knüpfer H; Van Gool S; Domula M; Wolff JE
Cytokine; 2000 Apr; 12(4):409-12. PubMed ID: 10805225
[TBL] [Abstract][Full Text] [Related]
4. Interferon-gamma inhibits proliferation and adhesion of T98G human malignant glioma cells in vitro.
Knüpfer MM; Poppenborg H; Van Gool S; Domula M; Wolff JE
Klin Padiatr; 1997; 209(4):271-4. PubMed ID: 9293461
[TBL] [Abstract][Full Text] [Related]
5. Valproic acid for the treatment of pediatric malignant glioma.
Driever PH; Knüpfer MM; Cinatl J; Wolff JE
Klin Padiatr; 1999; 211(4):323-8. PubMed ID: 10472571
[TBL] [Abstract][Full Text] [Related]
6. Targeting hyaluronan interactions in malignant gliomas and their drug-resistant multipotent progenitors.
Gilg AG; Tye SL; Tolliver LB; Wheeler WG; Visconti RP; Duncan JD; Kostova FV; Bolds LN; Toole BP; Maria BL
Clin Cancer Res; 2008 Mar; 14(6):1804-13. PubMed ID: 18347183
[TBL] [Abstract][Full Text] [Related]
7. CD44 expression and hyaluronic acid binding of malignant glioma cells.
Knüpfer MM; Poppenborg H; Hotfilder M; Kühnel K; Wolff JE; Domula M
Clin Exp Metastasis; 1999 Feb; 17(1):71-6. PubMed ID: 10390150
[TBL] [Abstract][Full Text] [Related]
8. Valproic acid induces polarization, neuronal-like differentiation of a subpopulation of C6 glioma cells and selectively regulates transgene expression.
Benítez JA; Arregui L; Cabrera G; Segovia J
Neuroscience; 2008 Oct; 156(4):911-20. PubMed ID: 18771712
[TBL] [Abstract][Full Text] [Related]
9. Valproic acid inhibits proliferation of human coronary vascular cells (SI/MPL-ratio: 0.5): a novel candidate for systemic and local therapy of postinterventional restenosis.
Voisard R; Krebs R; Baur R; Hombach V
Coron Artery Dis; 2010 Aug; 21(5):286-91. PubMed ID: 20508518
[TBL] [Abstract][Full Text] [Related]
10. Interferon-gamma inhibits growth and migration of A172 human glioblastoma cells.
Knüpfer MM; Knüpfer H; Jendrossek V; Van Gool S; Wolff JE; Keller E
Anticancer Res; 2001; 21(6A):3989-94. PubMed ID: 11911281
[TBL] [Abstract][Full Text] [Related]
11. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha.
Cinatl J; Kotchetkov R; Blaheta R; Driever PH; Vogel JU; Cinatl J
Int J Oncol; 2002 Jan; 20(1):97-106. PubMed ID: 11743648
[TBL] [Abstract][Full Text] [Related]
12. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide.
Kanzawa T; Kondo Y; Ito H; Kondo S; Germano I
Cancer Res; 2003 May; 63(9):2103-8. PubMed ID: 12727826
[TBL] [Abstract][Full Text] [Related]
13. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
[TBL] [Abstract][Full Text] [Related]
14. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of erucylphosphocholine on brain tumor cells in vitro and in vivo.
Erdlenbruch B; Jendrossek V; Marx M; Hunold A; Eibl H; Lakomek M
Anticancer Res; 1998; 18(4A):2551-7. PubMed ID: 9703909
[TBL] [Abstract][Full Text] [Related]
16. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.
Neri P; Tagliaferri P; Di Martino MT; Calimeri T; Amodio N; Bulotta A; Ventura M; Eramo PO; Viscomi C; Arbitrio M; Rossi M; Caraglia M; Munshi NC; Anderson KC; Tassone P
Br J Haematol; 2008 Nov; 143(4):520-31. PubMed ID: 18986388
[TBL] [Abstract][Full Text] [Related]
17. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
18. Growth inhibition and differentiation of C6 glioma cells on treatment with hmba.
Shirsat NV; Kayal JJ; Shaikh S; Mehta A
Cell Biol Int; 2001; 25(7):621-7. PubMed ID: 11448101
[TBL] [Abstract][Full Text] [Related]
19. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo.
Xia Q; Sung J; Chowdhury W; Chen CL; Höti N; Shabbeer S; Carducci M; Rodriguez R
Cancer Res; 2006 Jul; 66(14):7237-44. PubMed ID: 16849572
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status.
Travaglini L; Vian L; Billi M; Grignani F; Nervi C
Int J Biochem Cell Biol; 2009 Jan; 41(1):225-34. PubMed ID: 18789398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
